Sleep disordered breathing in cystic fibrosis - 23/08/11

Doi : 10.1016/j.smrv.2004.03.004

Maree A. Milross ^a,^b,⁎ , Amanda J. Piper ^a,^b,^{^{1
Amanda Piper is employed as a consultant to ResMed Pty Ltd, a manufacturer of mechanical devices used to treat sleep disordered breathing. She also holds a small number of share options with ResMed Pty Ltd. There are no other potential conflicts of interests relevant to this publication.}} , Catherine J. Dobbin ^a,^b , Peter T.P. Bye ^a,^b , Ronald R. Grunstein ^a,^b
^a Department of Respiratory Medicine, Royal Prince Alfred Hospital, Camperdown, Sydney NSW 2050, Australia
^b Woolcock Institute of Medical Research, University of Sydney, Sydney, 2006, Australia

Corresponding author. Address. Woolcock Institute of Medical Research, University of Sydney, Sydney, 2006, Australia. Tel.: +61-2-9515-8876; fax: +61-2-9515-7196

Abstract

Cough, sleep fragmentation and oxyhaemoglobin desaturation have all been documented during sleep in patients with cystic fibrosis (CF). It has been proposed that repeated episodes of nocturnal hypoxia act as a stimulus for the development of pulmonary hypertension and right ventricular failure, a complication that is associated with a poor prognosis. In addition, sleep disturbance from these events could lead to poor daytime function and quality of life. This review provides a detailed description of the mechanisms underlying sleep disordered breathing in this population, what is known regarding its effects upon daytime function and current treatment options. Most importantly, we review what is needed from future research in this challenging area of care in patients with CF.

Le texte complet de cet article est disponible en PDF.

Keywords : Cystic fibrosis, Sleep hypoventilation, Sleep desaturation, Hypercapnia, Neurocognitive function